ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC
- Author(s)
- Schmid, S; Dimopoulou, G; van Schil, P; Konig, D; Mauti, L; Itchins, M; Fruh, M; Oselin, K; Landi, L; Perol, M; Popat, S; Aigner, C; Forde, P; de Jong, WK; Roschitzki-Voser, H; Grolimund, E; Ruepp, B; Solomon, B; Finn, S; Dafni, U; Stahel, R; Peters, S; ETOP 25-23 ADOPT-lung collaborators;
- Journal Title
- Lung Cancer
- Publication Type
- Protocol
- Department(s)
- Medical Oncology
- Publisher's Version
- https://doi.org/10.1016/j.lungcan.2025.108635
- Open Access at Publisher's Site
https://doi.org/10.1016/j.lungcan.2025.108635- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-08-08 07:40:17
Last Modified: 2025-08-08 07:42:02